LABORATORIO FARMAC.ERFO Total Liabilities
LABORATORIO FARMAC.ERFO total liabilities. Based on the latest financial reports, LABORATORIO FARMAC.ERFO (RK7) has total liabilities worth €2.98 Million EUR (≈ $3.48 Million USD) as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See LABORATORIO FARMAC.ERFO liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of LABORATORIO FARMAC.ERFO (2021–2023)
Total liabilities of LABORATORIO FARMAC.ERFO from 2021 to 2023. This chart illustrates how LABORATORIO FARMAC.ERFO's total liabilities have evolved over time, based on quarterly financial data.
LABORATORIO FARMAC.ERFO Competitors by Total Liabilities
The table below lists competitors of LABORATORIO FARMAC.ERFO ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Stamper Oil & Gas Corp
V:STMP
|
Canada | CA$3.44 Million |
|
Akkhie Prakarn Public Company Limited
BK:AKP
|
Thailand | ฿97.27 Million |
|
Jaya Trishindo Tbk PT
JK:HELI
|
Indonesia | Rp99.55 Billion |
|
Holand og Setskog Sparebank
OL:HSPG
|
Norway | Nkr8.13 Billion |
|
W.A.G payment solutions plc
LSE:EWG
|
UK | GBX877.91 Million |
|
Gulf & Pacific Equities Corp
V:GUF
|
Canada | CA$28.54 Million |
|
Duketon Mining Ltd
AU:DKM
|
Australia | AU$349.57K |
|
SSH GROUP LTD
F:JRSA
|
Germany | €31.15 Million |
Liability Composition Analysis (2021–2023)
This chart breaks down LABORATORIO FARMAC.ERFO's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see LABORATORIO FARMAC.ERFO assets under control.
Liquidity & Leverage Metrics
LABORATORIO FARMAC.ERFO Total Liabilities Ratios Explained
LABORATORIO FARMAC.ERFO total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how LABORATORIO FARMAC.ERFO's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for LABORATORIO FARMAC.ERFO (2021–2023)
The table below shows the annual total liabilities of LABORATORIO FARMAC.ERFO from 2021 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | €2.26 Million ≈ $2.65 Million |
-78.50% |
| 2022-12-31 | €10.53 Million ≈ $12.32 Million |
+377.53% |
| 2021-12-31 | €2.21 Million ≈ $2.58 Million |
-- |
About LABORATORIO FARMAC.ERFO
Laboratorio Farmaceutico Erfo S.p.A. engages in the formulation and production of food supplements in Italy. It produces various types of pharmaceutical forms, such as bottles, single-dose vials and bottles, capsules, tablets, and sachets under the Diètnatural and Gianopharma brands, as well as private label brands. The company offers custom formula creation, regulatory advice, graphics, and pack… Read more